U.S. 503B Compounding Pharmacies Market

U.S. 503B Compounding Pharmacies Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 150-179

U.S. 503B Compounding Pharmacies Market

To learn more about this report, request a free sample copy

503B Compounding Pharmacies Market Overview

The report is titled as ‘503B Compounding Pharmacies Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the 503B Compounding Pharmacies market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. 503B Compounding Pharmacies market is expected to grow with significant rate in the near future.

In 2020, U.S. 503B Compounding Pharmacies market was valued at US$ 866.3 Mn and expected to grow significantly at a CAGR of 7.3% over the forecast period

Introduction

In the sphere of pharmacy, compounding can refer to the formulation of a custom compound or mixture of a medication to correspond to a special need of a patient that cannot be achieved with commercially available products. To quote the instance offered by Linda D. Bentley, JD, chair of the FDA practice group, a person is likely to be sensitized to one of the constituents in the commercial form of a drug. In such instances, a compounding pharmacy carried the capacity to make the appropriate form and dosage of the drug without any provoking constituents.

Given the fact that regulators have undertaken assigning higher scrutiny on compounding pharmacies subsequent incidents related to poor inadvertence by state boards of pharmacy, FDA has categorized these pharmacies into two segments: 503A and 503B. The FDA has specified 503B compounding pharmacies as those including outsourcing facilities that have the capability to generate large batches with or without prescriptions to put up for sale to healthcare facilities only for office use. Moreover, these pharmacies also possess the authority to use larger batches to lessen their manufacturing costs, shifting the savings over consumers.

Market Dynamics

In the present items, the growing prevalence of chronic diseases as well as growing geriatric population is majorly causing the increased drug shortage all around the world, ultimately boosting the demand of compounding pharmacies. To support that, as per the report by the U.S. Food and Drug Administration (FDA): Drug Shortages: Root Causes and Potential Solutions 2019, about 36.6% hospitals exclaimed that they had rescheduled non-urgent or emergent procedures and 56% of hospitals stated they had made amends in patient care or delayed therapy taking into account drug shortages. Owing to which, the 503B compounding pharmacies market is projected to rise significantly in the following years.

In addition to that, the U.S. FDA further published guidelines according to which the FDA will not be taking any action against outsourcing facilities. These regulations comprise conditions such as outsourcing facilities manufacturing compounding drugs that is largely a replicate of a certified drug. Such factors are further projected to propel the growth of the 503B compounding pharmacies market over the forecast period.

Furthermore, the leading players of the market are heavily engaged in organic activities such as partnerships and new product launches in order to overpower the increasing drug shortage problems. For instance, Piramal Critical Care (PCC), in July 2020, joined hands with Medivant Healthcare, a U.S. based pharmaceutical outsourcing facility, in the form of strategic partnership in order to address the serious shortage of injectable drugs in hospitals all across the United States. Attributing to such factors, the 503B compounding pharmacies market is expected to witness considerable growth in the coming years.

Reports & Insights Overview

The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.

A research report on the 503B Compounding Pharmacies market by Reports and Insights is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market. Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.

503B Compounding Pharmacies Market Segmentation

The U.S. 503B Compounding Pharmacies market is segmented on the basis of molecule, packaging, and compounding type

By Molecule

Acetaminophen

Phenylephrine

Midazolam

Esmolol

Vancomycin

Epinephrine

Adenocaine

Fentanyl/Bupivacaine

Morphine

Amiodarone

Heparin

Ketamine

Dextrose

Hydromorphone

Bupivacaine

Lidocaine

BKK (Bupivacaine, Ketorolac, and Ketamine)

RCK (Ropivacaine, Clonidine, and Ketorolac)

RKK (Ropivacaine, Ketorolac, and Ketamine)

Other Molecules

 

By Packaging

Vials

Prefilled Syringes

Ampoules

Syringes

Others

 

By Compounding Type

Hormone Replacement Therapy (HRT)

Men's Health Compounding

Pain Management Compounding

Pediatric Compounding

Veterinary Compounding

Geriatric Compounding

 

503B Compounding Pharmacies Market Key Players

Some of the key participating players in U.S. 503B Compounding Pharmacies market are:

Central Admixture Pharmacy Services, Inc.

Nephron Pharmaceuticals Corporation

QuVa Pharma

Olympia Pharmacy

ASP Cares

Fagron Compounding Pharmacies

Athenex, Inc.

Avella Specialty Pharmacy

Atlas Pharmaceuticals

Empower Pharmacy

Carie Boyd’S Prescription Shop

Edge Pharma

Imprimis NJOF, LLC

IntegraDose Compounding services, LLC

Wells Pharma of Houston, LLC

US Compounding Inc.

SCA Pharma

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance

Reimbursement

Concerns for use of 503B Compounding Pharmacies

Advantages of 503B Compounding Pharmacies

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries U.S.ly for providing regional insights of the product segment in the report. This helps our clients to take informed decision.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the market.


Summarized Info Details
Base Year: 2020 Forecast Period: 2021-2028
Key Geographies:
  • The United States of America
Market Segmentation:
  • The U.S. 503B Compounding Pharmacies market is segmented on the basis of molecule, packaging, and compounding type
Key Players:

Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’S Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma

Key Dynamics:
  • The growing prevalence of chronic diseases as well as growing geriatric population is majorly causing the increased drug shortage all around the world, ultimately boosting the demand of compounding pharmacies
Market Size: US$ 866.3 Mn in 2020 CAGR: 7.3%

To learn more about this report, request a free sample copy


1.    U.S. 503B Compounding Pharmacies Market Report Overview

1.1.    Introduction

1.2.    Report Description

1.3.    Methodology

2.    U.S. 503B Compounding Pharmacies Market Overview

2.1.    Introduction

2.1.1.    Introduction

2.1.2.    Market Taxonomy

2.2.    Executive Summary

2.3.    U.S. 503B Compounding Pharmacies Market Snapshot

2.4.    U.S. 503B Compounding Pharmacies Market Size And Forecast, 2020–2028

2.4.1.    Introduction

2.4.2.    Market Value Forecast And Annual Growth Rate (AGR) Comparison (2020–2028)

2.5.    U.S. 503B Compounding Pharmacies Market Dynamics

2.5.1.    Drivers

2.5.2.    Restraints

2.5.3.    Opportunity

2.5.4.    Trends

2.6.    Porter’s Five Forces Model

2.7.    SWOT Analysis

2.8.    PEST Analysis

2.9.    Supply Chain Analysis

3.    503B Compounding Pharmacies Assessment and Analysis

3.1.    503B Compounding Pharmacies Impact Analysis

3.2.    Value Chain Analysis

3.3.    Potential Analysis

4.    Covid-19 Impact on 503B Compounding Pharmacies Market

5.    U.S. 503B Compounding Pharmacies Market, By Product Type

5.1.    Introduction

5.1.1.    Annual Growth Rate Comparison, By Product Type

5.1.2.    BPS Analysis, By Product Type

5.2.    Market Revenue (US$Mn) and Forecast, By Product Type

5.2.1.    Acetaminophen

5.2.2.    Phenylephrine

5.2.3.    Midazolam

5.2.4.    Esmolol

5.2.5.    Vancomycin

5.2.6.    Epinephrine

5.2.7.    Adenocaine

5.2.8.    Fentanyl/Bupivacaine

5.2.9.    Morphine

5.2.10.    Amiodarone

5.2.11.    Heparin

5.2.12.    Ketamine

5.2.13.    Dextrose

5.2.14.    Hydromorphone

5.2.15.    Bupivacaine

5.2.16.    Lidocaine

5.2.17.    BKK (Bupivacaine, Ketorolac, and Ketamine)

5.2.18.    RCK (Ropivacaine, Clonidine, and Ketorolac)

5.2.19.    RKK (Ropivacaine, Ketorolac, and Ketamine)

5.2.20.    Other Molecules

5.3.    U.S. 503B Compounding Pharmacies Market Attractiveness Index, By Product Type

6.    U.S. 503B Compounding Pharmacies Market, By Packaging Type

6.1.    Introduction

6.1.1.    Annual Growth Rate Comparison, By Packaging Type

6.1.2.    BPS Analysis, By Packaging Type

6.2.    Market Revenue (US$Mn) and Forecast, By Packaging Type

6.2.1.    Vials

6.2.2.    Prefilled Syringes

6.2.3.    Ampoules

6.2.4.    Syringes

6.2.5.    Others

6.3.    U.S. 503B Compounding Pharmacies Market Attractiveness Index, By Packaging Type

7.    U.S. 503B Compounding Pharmacies Market, By Compounding Type

7.1.    Introduction

7.1.1.    Annual Growth Rate Comparison, By Compounding Type

7.1.2.    BPS Analysis, By Compounding Type

7.2.    Market Revenue (US$Mn) and Forecast, By Compounding Type

7.2.1.    Hormone Replacement Therapy (HRT)

7.2.2.    Men's Health Compounding

7.2.3.    Pain Management Compounding

7.2.4.    Pediatric Compounding

7.2.5.    Veterinary Compounding

7.2.6.    Geriatric Compounding

7.3.    U.S. 503B Compounding Pharmacies Market Attractiveness Index, By Compounding Type

8.    Competitive Landscape

8.1.    Competition Dashboard

8.2.    Company Share Analysis

8.3.    Company Profiles

8.3.1.    Central Admixture Pharmacy Services, Inc.

8.3.1.1.    Company overview

8.3.1.2.    Financial overview

8.3.1.3.    Key developments

8.3.1.4.    Swot analysis

8.3.1.5.    Strategies

8.3.1.6.    Product analysis

8.3.2.    Nephron Pharmaceuticals Corporation

8.3.3.    QuVa Pharma

8.3.4.    Olympia Pharmacy

8.3.5.    ASP Cares

8.3.6.    Fagron Compounding Pharmacies

8.3.7.    Athenex, Inc.

8.3.8.    Avella Specialty Pharmacy

8.3.9.    Atlas Pharmaceuticals

8.3.10.    Empower Pharmacy

8.3.11.    Carie Boyd’S Prescription Shop

8.3.12.    Edge Pharma

8.3.13.    Imprimis NJOF, LLC

8.3.14.    IntegraDose Compounding services, LLC

8.3.15.    Wells Pharma of Houston, LLC

8.3.16.    US Compounding Inc.

8.3.17.    SCA Pharma

9.    Acronyms

Select License Type

Frequently Asked Questions

Compounding can refer to the formulation of a custom compound or mixture of a medication to correspond to a special need of a patient that cannot be achieved with commercially available products

The growing prevalence of chronic diseases as well as growing geriatric population is majorly causing the increased drug shortage all around the world, ultimately boosting the demand of compounding pharmacies

The U.S. 503B Compounding Pharmacies market is segmented on the basis of molecule, packaging, and compounding type

Some of the key participating players in U.S. 503B Compounding Pharmacies market are Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’S Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma



This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK